Search the GHTC website

Global health R&D delivers for Illinois

US government investment in global health R&D has delivered

$60.9 million
to Illinois research institutions
850+ new jobs
for Illinois
Global health R&D at work in Illinois

Researchers at the University of Illinois College of Medicine at Rockford are conducting clinical trials of a vaccine candidate against lymphatic filariasis (LF), one of the world’s most profoundly disfiguring diseases. Commonly known as elephantiasis, LF is transmitted by mosquitos carrying parasitic worms. Currently, at least 36 million people worldwide are living with the severe pain, disability, and stigma of the disease; and 856 million people are at risk

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: CDC